###begin article-title 0
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
To examine whether small ubiquitin-like modifier 4 (SUMO4) polymorphisms were associated with Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Genotyping for SUMO4 polymorphisms at G-847A, A-504G, A+163G, and C+438T loci was performed on 231 VKH patients and 302 controls using polymerase chain reaction restriction fragment length polymorphism.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 206 214 206 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA)-DR4</italic>
###xml 219 228 219 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 305 308 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;16</sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 372 379 372 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 384 393 384 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 575 584 575 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 180 185 <span type="species:ncbi:9606">Human</span>
###xml 594 602 <span type="species:ncbi:9606">patients</span>
A decreased frequency of SUMO4 +438 TT genotype was found in VKH patients compared with healthy controls (p=0.009). However, the significance was lost after Bonferroni correction. Human leukocyte antigens (HLA)-DR4 and HLA-DRw53 were significantly associated with susceptibility to VKH syndrome (p=3.21x10-16 and 7.08x10-5, respectively). Stratification analysis based on HLA-DR4 and HLA-DRw53 did not show any associations between SUMO4 polymorphisms and VKH syndrome, although there was a big difference in the percentage of certain allele and genotype frequencies between HLA-DRw53 negative patients and controls. There was no significance in clinical findings and gender stratification analysis.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 12 21 12 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
HLA-DR4 and HLA-DRw53 are strongly associated with the susceptibility to VKH syndrome in the Chinese Han population. However, none of the currently known single nucleotide polymorphisms (SNPs) of SUMO4 are associated with this syndrome.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 735 736 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 737 738 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 795 798 795 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 800 803 800 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DR4</italic>
###xml 808 817 808 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 879 880 879 880 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 982 985 982 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 769 774 <span type="species:ncbi:9606">human</span>
Vogt-Koyanagi-Harada (VKH)syndrome is one of the most common uveitis entities in China [1]. It is characterized by a granulomatous panuveitis frequently in association with extraocular findings such as pleocytosis in the cerebrospinal fluid (CSF), dysacusis, alopecia, poliosis, and vitiligo [2-4]. Although the exact pathogenesis of VKH syndrome remains unclear, numerous studies have shown that immunogenetic factors are involved in the development of this syndrome. T cells autoreactive against tyrosinase family proteins are possibly involved in VKH syndrome. Meanwhile, genetic factors also play an important role in VKH syndrome as evidenced by the increased rates of this syndrome in pigmented groups [2], familial aggregation [5-7], and strong association with human leukocyte antigens (HLA)-DR4 and HLA-DRw53 in various ethnic groups including the Chinese and Japanese [8-10]. However, little is known about the genes that present susceptibility to the VKH syndrome except HLA [11-13].
###end p 11
###begin p 12
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
Recently, studies have demonstrated that multiple autoimmune diseases may share common susceptibility genes by whole genome association and family based association studies [14-17]. Therefore, susceptibility genes associated with other autoimmune diseases may be candidates in the study of gene susceptibility to VKH syndrome, an autoimmune uveitis commonly seen in China. Small ubiquitin-like modifier 4 (SUMO4) is located on chromosome 6p25. Recently, certain SUMO4 polymorphisms have been shown to be clearly associated with type 1 diabetes in multiple Asian populations [18,19] as well as with other autoimmune diseases [19-22], despite controversial observations in Caucasians [18,23-25]. SUMO4 polymorphisms could also be involved in the pathogenesis of VKH syndrome, and this hypothesis was therefore the subject of the study presented here.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects
###end title 14
###begin p 15
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Blood samples were collected from 231 Chinese Han VKH patients (128 males and 103 females) and 302 age- and sex-matched, unrelated Chinese Han healthy controls (164 males and 138 females), which were recruited from the Uveitis Study Center of the Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China and The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China. The institutional ethics committee of Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China approved this study, and informed consent was obtained from all tested subjects.
###end p 15
###begin title 16
DNA extraction
###end title 16
###begin p 17
###xml 160 168 <span type="species:ncbi:9606">patients</span>
Genomic DNA samples were extracted and isolated from ethylene diamine tetraacetic acid (EDTA) anti-coagulated peripheral blood mononuclear cells (PBMCs) of VKH patients and healthy controls by a conventional salting out method. These DNA samples were diluted in PCR grade water and stored at -70 degreesC until used.
###end p 17
###begin title 18
Genotyping
###end title 18
###begin p 19
###xml 1003 1010 979 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 1114 1116 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1119 1128 1095 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1179 1181 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
Polymerase chain reaction (PCR) was performed using primers at G-847A locate (Forward, 5'-TCC CAA CCA ATA ATA GCA AGT CT-3'; Reverse, 5'-ATG CCT GGA TCA AAA CAC ACA-3'), A-504G locate (Forward, 5'- TGT GTG TTT TGA TCC AGG CAT TA-3'; Reverse, 5'-TGT TTT GCT CCT CTT TTC CTC TT-3'), A+163G locate (Forward, 5'-ATT GTG AAC CAC GGG GAT TGT TA-3'; Reverse, 5'-CAGCGTTCTGGAGTAAAGAAG-3'), and C+438T locate (Forward, 5'-ATA CCA GTT ACT TCA TGT ATA ATA GA-3'; Reverse, 5'-AGA TTA CTG CAT TCT CAA TTA G -3'). PCR products at G-847A (), A-504G (), A+163G (), and C+438T () loci were incubated with SspI at 37 degreesC, Alw21I at 37 degreesC, MseI at 65 degreesC, and MnlI at 37 degreesC (MBI Fermentas, Vilnius, Lithuania) for at least 4 h, respectively. PCR fragments were separated on 3% agarose gels. Twenty percent of the PCR samples were directly sequenced to confirm the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) results (Invitrogen Biotechnology Co., Guangzhou, China). HLA-DR4 genotyping was performed using the PCR sequence specific primers (SSP) method as previously described [26]. HLA-DRw53 genotyping was performed as previously described [27].
###end p 19
###begin title 20
Statistical analysis
###end title 20
###begin p 21
###xml 7 8 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 82 83 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 402 404 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 405 407 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
The chi2 test was applied to analyze the Hardy-Weinberg equilibrium (HWE). The chi2 test or Fisher's exact test was performed to compare the allelic, genotypic, and haplotypic distribution between VKH patients and healthy controls using version 12.0 of SPSS for Windows (SPSS Inc., Chicago, IL). Analysis of linkage disequilibrium (LD) of each SNP and haplotype was performed using the  v3.32 program [28,29]. The p values were corrected using the Bonferroni correction to account for multiple testing. Sample sizes were estimated by Quanto 1.2 software (Department of Preventive Medicine, University of Southern California, Los Angles, CA).
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
###xml 31 39 <span type="species:ncbi:9606">patients</span>
Descriptive data of the tested patients and controls
###end title 23
###begin p 24
###xml 69 75 69 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table1</xref>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
Detailed clinical findings of the enrolled VKH patients are shown in Table1. The average age of the VKH patients was 33.6+/-12.4 years and that of healthy controls was 35.4+/-12.0 years. No statistical difference was observed between VKH patients and controls in the distribution of age and gender (p>0.05).
###end p 24
###begin title 25
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 12 22 12 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53 </italic>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
HLA-DR4 and HLA-DRw53 distribution and clinical findings of patients with VKH syndrome.
###end title 25
###begin p 26
###xml 42 50 <span type="species:ncbi:9606">patients</span>
The age at onset (years+/-SD) for all VKH patients was 33.6+/-12.4 years.
###end p 26
###begin title 27
###xml 79 84 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
Single nucleotide polymorphism and haplotype analyses between polymorphisms of SUMO4 and Vogt-Koyanagi-Harada syndrome
###end title 27
###begin p 28
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 284 285 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 361 368 359 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 123 131 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
The distribution of genotype for each SNP including G-847A, A-504G, A+163G, and C+438T did not deviate from the HWE in VKH patients and healthy controls (p>0.05). A decreased frequency of SUMO4 +438 TT genotype was observed in VKH patients compared with healthy controls (p=0.009, chi2=9.36). However, it did not remain significant after Bonferroni correction (Table 2).
###end p 28
###begin title 29
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4 </italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
The comparison of allele and genotype frequencies for the four polymorphisms of SUMO4 gene in VKH patients and controls.
###end title 29
###begin p 30
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
a Bonferroni corrected p value; bNot significant.
###end p 30
###begin p 31
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 252 253 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 325 332 323 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
Haplotype analysis using the  3.32 software showed that the four SNPs were in strong linkage (D'=84-91). A decreased frequency of SUMO4 haplotype (-847A, -504G, +163A, and +438T) was observed in VKH patients compared with healthy controls (p=0.008, chi2=7.07). However, the significance was lost after Bonferroni correction (Table 3).
###end p 31
###begin title 32
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 57 65 <span type="species:ncbi:9606">Patients</span>
The comparison of frequencies of SUMO4 haplotypes in VKH Patients and controls.
###end title 32
###begin p 33
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
a Bonferroni corrected p value; bNot significant.
###end p 33
###begin title 34
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
Stratification analysis of SUMO4 polymorphisms with the status of HLA-DR4, HLA-DRw53, the clinical findings, and gender
###end title 34
###begin p 35
###xml 39 46 39 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 171 174 171 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;16</sup>
###xml 179 180 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 218 227 216 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 370 372 368 370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 377 378 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 456 463 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 468 473 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRw53</italic>
###xml 481 486 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 625 630 621 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 658 665 654 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 688 695 684 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 726 733 722 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 756 763 752 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 783 790 779 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 831 840 827 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 866 873 862 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 918 927 914 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 960 969 956 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1010 1019 1006 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1037 1046 1033 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1091 1100 1087 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1118 1127 1114 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1180 1189 1176 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1207 1216 1203 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1258 1267 1254 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1285 1294 1281 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1347 1356 1343 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1374 1383 1370 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1428 1437 1424 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1455 1464 1451 1460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 1496 1503 1492 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
###xml 937 945 <span type="species:ncbi:9606">patients</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
###xml 1191 1199 <span type="species:ncbi:9606">patients</span>
###xml 1269 1277 <span type="species:ncbi:9606">patients</span>
###xml 1358 1366 <span type="species:ncbi:9606">patients</span>
###xml 1439 1447 <span type="species:ncbi:9606">patients</span>
Our study showed that the frequency of HLA-DR4 was significantly increased in 231 VKH patients as compared with that in 302 healthy controls (77.5% versus 19.5%, p=3.21x10-16, chi2=66.67, OR=13.74, 95% CI=6.99-26.98). HLA-DRw53 was also shown to be significantly associated with susceptibility to VKH syndrome in the Chinese Han population (87.9% versus 63.9%, p=7.08x10-5, chi2=15.79, OR=4.13, 95% CI=1.99-8.55). To test whether there was an influence of HLA-DR4 and DRw53 on the SUMO4 association, stratification analysis was performed according to these parameters. The allele and genotype frequencies of the four SNPs of SUMO4 were not different between HLA-DR4 positive patients and HLA-DR4 positive controls and between HLA-DR4 negative patients and HLA-DR4 negative controls (Table 4). Similar results were also observed in HLA-DRw53 stratification analysis (Table 5). However, a big difference was observed in HLA-DRw53 negative patients compared with HLA-DRw53 negative controls (G-847A: AA genotype, HLA-DRw53- patients versus HLA-DRw53- controls: 40.7% versus 59.4%, AG genotype, HLA-DRw53- patients versus HLA-DRw53- controls: 48.1% versus 31.1%; A-504G: AA genotype, HLA-DRw53- patients versus HLA-DRw53- controls: 40.8% versus 21.5%, A allele, HLA-DRw53- patients versus HLA-DRw53- controls: 59.3% versus 43.9%; A+163G: AA genotype, HLA-DRw53- patients versus HLA-DRw53- controls: 39.3% versus 56.9%, AG genotype, HLA-DRw53- patients versus HLA-DRw53- controls: 50.0% versus 33.0%; Table 5).
###end p 35
###begin title 36
###xml 28 35 28 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4 </italic>
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> HLA-DR4</italic>
###xml 151 158 151 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 173 180 173 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 198 205 198 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Stratification analysis for HLA-DR4 and SUMO4 polymorphisms and the comparison of frequencies of SUMO4 allele and genotype in HLA-DR4+ patients versus HLA-DR4+ controls and HLA-DR4- patients versus HLA-DR4- controls.
###end title 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
a Bonferroni corrected p value; bNot significant.
###end p 37
###begin title 38
###xml 28 37 28 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4 </italic>
###xml 127 137 127 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> HLA-DRw53</italic>
###xml 155 164 155 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 179 188 179 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 206 215 206 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
Stratification analysis for HLA-DRw53 and SUMO4 polymorphisms and the comparison of frequencies of SUMO4 allele and genotype in HLA-DRw53+ patients versus HLA-DRw53+ controls and HLA-DRw53- patients versus HLA-DRw53- controls.
###end title 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
aBonferroni corrected p value; bNot significant.
###end p 39
###begin p 40
###xml 324 329 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
Stratification analysis was also performed according to clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusis, scalp hypersensitivity, and vitiligo. No association was found between the four SNPs and any extraocular findings. The analysis of gender stratification also showed no association of SUMO4 polymorphisms with VKH syndrome.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 232 239 232 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 241 250 241 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
In this study, we examined the association of SUMO4 polymorphisms with VKH syndrome in the Chinese Han population. Our results failed to find an association between SUMO4 polymorphisms and VKH syndrome even after stratification for HLA-DR4, HLA-DRw53, clinical features, and gender.
###end p 42
###begin p 43
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 57 79 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NF-&#1082;B</italic>
###xml 169 174 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 446 448 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 634 636 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 881 886 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 1107 1109 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1517 1519 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 1577 1579 1560 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1767 1772 1750 1755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
###xml 1230 1238 <span type="species:ncbi:9606">patients</span>
SUMO4 has been shown to be involved in the regulation of NF-small ka, CyrillicB, an important transcription factor in autoimmune diseases. It has been reported that the SUMO4 A+163G (M55V) polymorphism is an essential polymorphism involved in regulating its own sumoylation, and it has been shown to be associated with certain autoimmune diseases such as type 1 diabetes, autoimmune thyroid disease, and rheumatoid arthritis without amyloidosis [19]. These results suggest that this polymorphism could be a susceptibility gene shared by certain autoimmune diseases, although conflicting data have been reported in Sjogren's syndrome [19]. The identification of a general susceptibility gene for several autoimmune diseases could make an important contribution to the understanding of the pathogenesis and modulation of these diseases. The question was therefore raised whether the SUMO4 A+163G polymorphism was also associated with VKH syndrome. This study was designed to clarify this issue. We strictly chose the patients who were definitely diagnosed with VKH syndrome according to the revised criteria [30] to exclude the influence of misdiagnosis. As ethnic confounding could also influence the association results, only VKH patients with Chinese Han nationality as well as age- and sex-matched controls with the same nationality were enrolled in this study. The frequency of the +163G allele in the control population presented in our study is similar with that in the Chinese population reported by Li et al. [31] and in the Japanese population reported by Noso et al. [20]. Meanwhile, a power analysis of the study population showed that our sample size was large enough to detect a possible association. Unexpectedly, we failed to find an association of the SUMO4 A+163G polymorphism with VKH syndrome. This suggests that this polymorphism may not be involved in the development of susceptibility to VKH syndrome.
###end p 43
###begin p 44
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
Others SNPs including G-847A, A-504G, and C+438T polymorphisms have been identified by direct sequencing of the whole SUMO4 gene in the Japanese population [20,32]. Our previous results showed an association of SUMO4 C+438T polymorphism with Behcet's disease [22], another common uveitis entity observed in China. The present study also failed to show any association of the SUMO4 G-847A, A-504G, and C+438T polymorphisms with VKH syndrome. This difference may result from the different features of these two uveitis entities. One of the striking features of Behcet's disease is its characteristic non-granulomatous inflammation while VKH syndrome is in fact a granulomatous inflammation [33].
###end p 44
###begin p 45
###xml 5 23 5 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4, HLA-DRw53</italic>
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 129 138 129 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 173 180 173 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 185 194 185 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 415 422 415 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 427 436 427 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 611 614 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 688 693 688 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
Like HLA-DR4, HLA-DRw53 have been demonstrated to be strongly associated with VKH syndrome. Therefore, genotyping of HLA-DR4 and HLA-DRw53 was performed. The association of HLA-DR4 and HLA-DRw53 with VKH syndrome was extremely strong in this study. The results were generally consistent with those previously reported in Chinese [4,8,34] and Spanish patients [35]. Furthermore, stratification analysis according to HLA-DR4 and HLA-DRw53 did not show any association of SUMO4 with VKH syndrome in our study. This result is consistent with the previous studies that SUMO4 M55V polymorphism was independent of the HLA class II haplotype [19,32], which is located on the same chromosome 6 as SUMO4.
###end p 45
###begin p 46
###xml 118 127 118 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 246 255 246 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 340 345 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 365 374 365 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
It is worthy to point out that there was a big difference in the percentages of certain alleles and genotypes between HLA-DRw53 negative patients and controls, although the difference did not reach statistical significance. As the sample size of HLA-DRw53 negative is small (28 patients), it is necessary to further test the association of SUMO4 polymorphisms with HLA-DRw53 negative patients using larger samples.
###end p 46
###begin p 47
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 186 193 186 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DR4</italic>
###xml 198 207 198 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 326 335 326 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 373 382 373 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 464 469 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SUMO4</italic>
###xml 507 516 507 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRw53</italic>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
In conclusion, we failed to detect an association of SUMO4 polymorphisms with VKH syndrome in Chinese Han population. In agreement with earlier studies, we found a strong association of HLA-DR4 and HLA-DRw53 with susceptibility to VKH syndrome. A big but insignificant difference of allele and genotype frequency was noted in HLA-DRw53 negative patients when compared with HLA-DRw53 negative controls. Further studies are necessary to elucidate the association of SUMO4 polymorphisms with VKH syndrome in a HLA-DRw53 negative population using larger samples.
###end p 47
###begin title 48
Acknowledgments
###end title 48
###begin p 49
This work was supported by Project of International Cooperation in Science and Technology, Guangdong Province (2006A50107001), Key Project of Natural Science Foundation (30630064), National supporting project of P.R. China and Key Project of Health Bureau and Key Project of Science and Technology Committee of Chongqing. Thanks to all subjects enrolled in the present study.
###end p 49
###begin title 50
References
###end title 50
###begin article-title 51
Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China.
###end article-title 51
###begin article-title 52
Vogt-Koyanagi-Harada syndrome.
###end article-title 52
###begin article-title 53
Echographic features of the Vogt-Koyanagi-Harada syndrome.
###end article-title 53
###begin article-title 54
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.
###end article-title 54
###begin article-title 55
Vogt-Koyanagi-Harada disease in identical twins.
###end article-title 55
###begin article-title 56
Simultaneous onset of Vogt-Koyanagi-Harada syndrome in monozygotic twins.
###end article-title 56
###begin article-title 57
Vogt-Koyanagi-Harada disease in monozygotic twins.
###end article-title 57
###begin article-title 58
Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population.
###end article-title 58
###begin article-title 59
###xml 10 15 <span type="species:ncbi:9606">human</span>
Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.
###end article-title 59
###begin article-title 60
HLA class II genes in Vogt-Koyanagi-Harada disease.
###end article-title 60
###begin article-title 61
Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome.
###end article-title 61
###begin article-title 62
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients.
###end article-title 62
###begin article-title 63
Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease.
###end article-title 63
###begin article-title 64
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 64
###begin article-title 65
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
###end article-title 65
###begin article-title 66
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.
###end article-title 66
###begin article-title 67
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
###end article-title 67
###begin article-title 68
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
###end article-title 68
###begin article-title 69
Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population.
###end article-title 69
###begin article-title 70
Association of small ubiquitin-like modifier 4 (SUMO4) variant, located in IDDM5 locus, with type 2 diabetes in the Japanese population.
###end article-title 70
###begin article-title 71
SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes.
###end article-title 71
###begin article-title 72
###xml 40 48 <span type="species:ncbi:9606">patients</span>
SUMO4 gene polymorphisms in Chinese Han patients with Behcet's disease.
###end article-title 72
###begin article-title 73
A 212-kb region on chromosome 6q25 containing the TAB2 gene is associated with susceptibility to type 1 diabetes.
###end article-title 73
###begin article-title 74
Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes.
###end article-title 74
###begin article-title 75
Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes.
###end article-title 75
###begin article-title 76
Identification of the HLA-DRB1*04, -DRB1*07, and -DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours.
###end article-title 76
###begin article-title 77
HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
###end article-title 77
###begin article-title 78
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 78
###begin article-title 79
Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.
###end article-title 79
###begin article-title 80
Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.
###end article-title 80
###begin article-title 81
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris.
###end article-title 81
###begin article-title 82
Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes.
###end article-title 82
###begin article-title 83
Choroidal neovascularization in long-standing case of Vogt-Koyanagi-Harada disease.
###end article-title 83
###begin article-title 84
The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome.
###end article-title 84
###begin article-title 85
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.
###end article-title 85

